Dasatinib 50mg

Dasatinib 50 mg belongs to the group of drugs known as TKIs (protein tyrosine kinase inhibitors). These are proteins that work as chemical messengers stimulating the growth of tumor cell. Dasatinib prevents the tyrosine kinases from transmitting the signals that make the cancer cells grow.
Dasatinib is intended for the treatment of chronic myeloid leukemia (a cancer of the white blood cells) as a first-line therapy and in patients who can’t use other leukemia drugs such as Imatinib due to the adverse effects or allergy. Moreover, Dasatinib 50 mg is intended for the treatment of a childhood ALL (acute lymphoblastic leukemia; a kind of cancer where the bone marrow produces too many immature lymphocytes). Dasatinib belongs to the group of drugs known as “kinase inhibitors”. It acts by preventing the activity of an abnormal protein, which stimulate the tumor cells to replicate. This allows preventing the spread of tumor cells.

How to use Dasatinib 50 mg?

Dasatinib should be taken once daily. Take the pills at the same time every day with a full glass of liquid. You can take the pill, irrespective of the mealtime. Avoid crushing and breaking the pills. Avoid taking the pills, which neutralize stomach acids (antacids) for at least 2 hours before and after the intake of Dasatinib. Don’t eat grapefruits, as this can enhance the risk of adverse effects.

Adverse effects

Seek immediate medical help if you notice any of these symptoms of an allergic response: rash; breathing problems; face swelling, etc.
Some patients taking Dasatinib 50 mg have experience a rare but severe disorder known as PAH pulmonary arterial hypertension. This happens when blood pressure enhances inside the pulmonary arteries (which makes it difficult for your heart to pump blood through the lungs and affect the condition of heart muscles). Pulmonary arterial hypertension may be irreversible if untreated, and this disease can cause death. Discuss the risk of PAH with your health care professional.

In 2010, Dasatinib was also approved by the FDA for the treatment of adults suffering from chronic Ph+ chronic myelogenous leukemia. The common dose of Dasatinib for this disease is 100 mg by mouth once a day. Sprycel was initially approved in 2006 for the therapy of adults suffering from CP-CML intolerant or resistant to the previous treatment (for example, Imatinib).